

# William E Carson Iii

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/968933/publications.pdf>

Version: 2024-02-01

198  
papers

12,332  
citations

22153

59  
h-index

31849

101  
g-index

201  
all docs

201  
docs citations

201  
times ranked

17692  
citing authors

#	ARTICLE	IF	CITATIONS
1	Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. <i>Blood</i> , 2001, 97, 3146-3151.	1.4	1,201
2	Psychologic intervention improves survival for breast cancer patients. <i>Cancer</i> , 2008, 113, 3450-3458.	4.1	408
3	Psychological, Behavioral, and Immune Changes After a Psychological Intervention: A Clinical Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 3570-3580.	1.6	351
4	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 367-402.	4.9	326
5	Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer. , 2013, 1, 10.		249
6	Pain, depression, and fatigue: Loneliness as a longitudinal risk factor.. <i>Health Psychology</i> , 2014, 33, 948-957.	1.6	234
7	Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology. <i>ACS Nano</i> , 2015, 9, 9731-9740.	14.6	220
8	Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 450-473.	4.9	203
9	BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 34-41.	1.6	172
10	Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function. <i>Clinical Cancer Research</i> , 2018, 24, 1891-1904.	7.0	172
11	Myeloid-Derived Suppressor Cell Inhibition of the IFN Response in Tumor-Bearing Mice. <i>Cancer Research</i> , 2011, 71, 5101-5110.	0.9	170
12	Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti-tumor mechanisms of Cannabidiol in breast cancer. <i>Molecular Oncology</i> , 2015, 9, 906-919.	4.6	170
13	Distress reduction from a psychological intervention contributes to improved health for cancer patients. <i>Brain, Behavior, and Immunity</i> , 2007, 21, 953-961.	4.1	159
14	A Progenitor Cell Expressing Transcription Factor ROR $\gamma$ t Generates All Human Innate Lymphoid Cell Subsets. <i>Immunity</i> , 2016, 44, 1140-1150.	14.3	153
15	Signaling pathways involved in MDSC regulation. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 55-65.	7.4	152
16	Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. <i>Cancer Research</i> , 2016, 76, 2125-2136.	0.9	150
17	Biobehavioral, Immune, and Health Benefits following Recurrence for Psychological Intervention Participants. <i>Clinical Cancer Research</i> , 2010, 16, 3270-3278.	7.0	143
18	Myeloid-derived suppressor cells in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 13-21.	2.5	143

#	ARTICLE	IF	CITATIONS
19	A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma. <i>Annals of Surgical Oncology</i> , 2007, 14, 2367-2376.	1.5	142
20	IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. <i>Journal of Clinical Investigation</i> , 2002, 110, 983-992.	8.2	142
21	Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2 /neu-positive breast cancer cells. <i>European Journal of Immunology</i> , 2001, 31, 3016-3025.	2.9	141
22	Defining the critical hurdles in cancer immunotherapy. <i>Journal of Translational Medicine</i> , 2011, 9, 214.	4.4	139
23	Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1269-1279.	4.2	134
24	Melanoma, Version 2.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 395-407.	4.9	134
25	Natural Killer Cells Produce T Cell-Recruiting Chemokines in Response to Antibody-Coated Tumor Cells. <i>Cancer Research</i> , 2006, 66, 517-526.	0.9	132
26	The Activation of Natural Killer Cell Effector Functions by Cetuximab-Coated, Epidermal Growth Factor Receptor-Positive Tumor Cells is Enhanced By Cytokines. <i>Clinical Cancer Research</i> , 2007, 13, 6419-6428.	7.0	131
27	Social support predicts inflammation, pain, and depressive symptoms: Longitudinal relationships among breast cancer survivors. <i>Psychoneuroendocrinology</i> , 2014, 42, 38-44.	2.7	129
28	CpG-Containing Oligodeoxynucleotides Act through TLR9 to Enhance the NK Cell Cytokine Response to Antibody-Coated Tumor Cells. <i>Journal of Immunology</i> , 2005, 175, 1619-1627.	0.8	115
29	Review of S100A9 biology and its role in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2013, 1835, 100-109.	7.4	114
30	IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. <i>Journal of Clinical Investigation</i> , 2002, 110, 983-992.	8.2	114
31	RAGE Mediates S100A7-Induced Breast Cancer Growth and Metastasis by Modulating the Tumor Microenvironment. <i>Cancer Research</i> , 2015, 75, 974-985.	0.9	112
32	Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2017, 35, 2028-2036.	1.6	111
33	Interleukin-21 Enhances NK Cell Activation in Response to Antibody-Coated Targets. <i>Journal of Immunology</i> , 2006, 177, 120-129.	0.8	109
34	CD56bright natural killer cell subsets: Characterization of distinct functional responses to interleukin-2 and the c-kit ligand. <i>European Journal of Immunology</i> , 1997, 27, 354-360.	2.9	108
35	A Phase I Study of Interleukin 12 with Trastuzumab in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressing Malignancies. <i>Clinical Cancer Research</i> , 2004, 10, 5027-5037.	7.0	108
36	The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. <i>Molecular Cancer</i> , 2010, 9, 165.	19.2	106

#	ARTICLE	IF	CITATIONS
37	A Psychological Intervention Reduces Inflammatory Markers by Alleviating Depressive Symptoms: Secondary Analysis of a Randomized Controlled Trial. <i>Psychosomatic Medicine</i> , 2009, 71, 715-724.	2.0	105
38	The antitumor effects of IFN- $\gamma$ are abrogated in a STAT1-deficient mouse. <i>Journal of Clinical Investigation</i> , 2003, 112, 170-180.	8.2	105
39	Postoperative Adjuvant Chemotherapy Use in Patients With Stage II/III Rectal Cancer Treated With Neoadjuvant Therapy: A National Comprehensive Cancer Network Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 30-38.	1.6	104
40	Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 149-159.	4.2	104
41	A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2983-2991.	4.1	100
42	NKp80 Defines a Critical Step during Human Natural Killer Cell Development. <i>Cell Reports</i> , 2016, 16, 379-391.	6.4	100
43	Generation of monocyte-derived tumor-associated macrophages using tumor-conditioned media provides a novel method to study tumor-associated macrophages in vitro. , 2019, 7, 140.		100
44	Precancerous Stem Cells Have the Potential for both Benign and Malignant Differentiation. <i>PLoS ONE</i> , 2007, 2, e293.	2.5	98
45	IL-12 Enhances the Antitumor Actions of Trastuzumab via NK Cell IFN- $\gamma$ Production. <i>Journal of Immunology</i> , 2011, 186, 3401-3409.	0.8	95
46	IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. <i>Blood</i> , 2008, 111, 4723-4730.	1.4	92
47	Cellular Immunity in Breast Cancer Patients Completing Taxane Treatment. <i>Clinical Cancer Research</i> , 2004, 10, 3401-3409.	7.0	88
48	Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients. <i>Cellular Immunology</i> , 2011, 270, 80-87.	3.0	86
49	Receptors for Interleukin (IL)-10 and IL-6-type Cytokines Use Similar Signaling Mechanisms for Inducing Transcription through IL-6 Response Elements. <i>Journal of Biological Chemistry</i> , 1996, 271, 13968-13975.	3.4	84
50	MiR-21 Enhances Melanoma Invasiveness via Inhibition of Tissue Inhibitor of Metalloproteinases 3 Expression: In Vivo Effects of MiR-21 Inhibitor. <i>PLoS ONE</i> , 2015, 10, e0115919.	2.5	83
51	Prospective Randomized Clinical Trial Comparing Intradermal, Intraparenchymal, and Subareolar Injection Routes for Sentinel Lymph Node Mapping and Biopsy in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2006, 13, 1412-1421.	1.5	79
52	Differential expression of SHIP1 in CD56 <sup>bright</sup> and CD56 <sup>dim</sup> NK cells provides a molecular basis for distinct functional responses to monokine costimulation. <i>Blood</i> , 2005, 105, 3011-3018.	1.4	76
53	NCCN Guidelines Insights: Melanoma, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 945-958.	4.9	76
54	Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors. <i>Journal of Clinical Oncology</i> , 2009, 27, 5270-5277.	1.6	75

#	ARTICLE	IF	CITATIONS
55	Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 5534-5539.	7.1	73
56	Multiparametric Flow Cytometric Analysis of Inter-Patient Variation in STAT1 Phosphorylation Following Interferon Alfa Immunotherapy. Journal of the National Cancer Institute, 2004, 96, 1331-1342.	6.3	72
57	Colocalization of the IL-12 receptor and FcγR1a to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-γ. Blood, 2008, 111, 4173-4183.	1.4	72
58	A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses. Journal of Immunology, 2003, 170, 4242-4253.	0.8	70
59	Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration. Scientific Reports, 2017, 7, 15424.	3.3	68
60	Inflammatory Cytokines and Comorbidity Development in Breast Cancer Survivors Versus Noncancer Controls: Evidence for Accelerated Aging?. Journal of Clinical Oncology, 2017, 35, 149-156.	1.6	68
61	Giant breast tumors: Surgical management of phyllodes tumors, potential for reconstructive surgery and a review of literature. World Journal of Surgical Oncology, 2008, 6, 117.	1.9	66
62	Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 366-400.	4.9	63
63	Melanoma, Version 4.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 621-629.	4.9	61
64	Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte FcγR Receptor (FcγR) Function. Journal of Biological Chemistry, 2016, 291, 3043-3052.	3.4	61
65	Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments. Brain, Behavior, and Immunity, 2007, 21, 185-194.	4.1	59
66	Cetuximab therapy in head and neck cancer: Immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Surgery, 2012, 152, 431-440.	1.9	58
67	Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunology, Immunotherapy, 2017, 66, 1437-1447.	4.2	58
68	Patterns of Recurrence After Sentinel Lymph Node Biopsy for Breast Cancer. Annals of Surgical Oncology, 2003, 10, 376-380.	1.5	57
69	Release of Biologically Functional Interferon-Alpha from a Nanochannel Delivery System. Biomedical Microdevices, 2005, 7, 71-79.	2.8	56
70	IFN-γ and Bortezomib Overcome Bcl-2 and Mcl-1 Overexpression in Melanoma Cells by Stimulating the Extrinsic Pathway of Apoptosis. Cancer Research, 2008, 68, 8351-8360.	0.9	54
71	Predicting Overall Survival in Patients With Metastatic Melanoma on Antiangiogenic Therapy and RECIST Stable Disease on Initial Posttherapy Images Using CT Texture Analysis. American Journal of Roentgenology, 2015, 205, W283-W293.	2.2	51
72	Delayed emotional recovery after taxane-based chemotherapy. Cancer, 2008, 113, 638-647.	4.1	49

#	ARTICLE	IF	CITATIONS
73	Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case-control analysis. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1471-1481.	4.2	48
74	MicroRNA dysregulation in melanoma. <i>Surgical Oncology</i> , 2016, 25, 184-189.	1.6	47
75	Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells. <i>BMC Cancer</i> , 2010, 10, 142.	2.6	46
76	A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2011, 34, 509-515.	2.4	46
77	Attachment anxiety is related to Epstein-Barr virus latency. <i>Brain, Behavior, and Immunity</i> , 2014, 41, 232-238.	4.1	46
78	IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. <i>Clinical Cancer Research</i> , 2017, 23, 489-502.	7.0	46
79	A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 83-89.	2.5	45
80	Interleukin-29 Binds to Melanoma Cells Inducing Jak-STAT Signal Transduction and Apoptosis. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 510-520.	4.1	44
81	Monosomy 3 status of uveal melanoma metastases is associated with rapidly progressive tumors and short survival. <i>Experimental Eye Research</i> , 2012, 100, 26-31.	2.6	44
82	Social support and socioeconomic status interact to predict Epstein-Barr virus latency in women awaiting diagnosis or newly diagnosed with breast cancer.. <i>Health Psychology</i> , 2012, 31, 11-19.	1.6	42
83	Ex vivo expansion of canine cytotoxic large granular lymphocytes exhibiting characteristics of natural killer cells. <i>Veterinary Immunology and Immunopathology</i> , 2013, 153, 249-259.	1.2	42
84	Phase III Randomized Study of 4 Weeks of High-Dose Interferon- $\alpha$ -2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group's American College of Radiology Imaging Network Cancer Research Group (E1697). <i>Journal of Clinical Oncology</i> , 2017, 35, 885-892.	1.6	42
85	Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function. <i>Scientific Reports</i> , 2019, 9, 5068.	3.3	40
86	Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. <i>Blood</i> , 2021, 137, 3473-3483.	1.4	40
87	Trajectories of Stress, Depressive Symptoms, and Immunity in Cancer Survivors: Diagnosis to 5 Years. <i>Clinical Cancer Research</i> , 2017, 23, 52-61.	7.0	39
88	Impaired Natural Killer Cell Lysis in Breast Cancer Patients with High Levels of Psychological Stress is Associated with Altered Expression of Killer Immunoglobulin-Like Receptors. <i>Journal of Surgical Research</i> , 2007, 139, 36-44.	1.6	37
89	Cognitive problems among breast cancer survivors: loneliness enhances risk. <i>Psycho-Oncology</i> , 2014, 23, 1356-1364.	2.3	37
90	PTEN Is a Negative Regulator of NK Cell Cytolytic Function. <i>Journal of Immunology</i> , 2015, 194, 1832-1840.	0.8	37

#	ARTICLE	IF	CITATIONS
91	Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy. <i>Surgical Oncology</i> , 2015, 24, 353-358.	1.6	37
92	Melanoma Cells Exhibit Variable Signal Transducer and Activator of Transcription 1 Phosphorylation and a Reduced Response to IFN- $\gamma$ Compared with Immune Effector Cells. <i>Clinical Cancer Research</i> , 2007, 13, 5010-5019.	7.0	36
93	STAT1-dependent and STAT1-independent gene expression in murine immune cells following stimulation with interferon-alpha. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1845-1852.	4.2	35
94	Reciprocal Regulation of Activating and Inhibitory Fc $\gamma$ 3 Receptors by TLR7/8 Activation: Implications for Tumor Immunotherapy. <i>Clinical Cancer Research</i> , 2010, 16, 2065-2075.	7.0	35
95	Fatigue and herpesvirus latency in women newly diagnosed with breast cancer. <i>Brain, Behavior, and Immunity</i> , 2012, 26, 394-400.	4.1	35
96	$\beta$ -Adrenergic receptor mediated increases in activation and function of natural killer cells following repeated social disruption. <i>Brain, Behavior, and Immunity</i> , 2012, 26, 1226-1238.	4.1	35
97	Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. <i>Onc Immunology</i> , 2012, 1, 1048-1060.	4.6	33
98	Multiparametric Flow Cytometric Analysis of Signal Transducer and Activator of Transcription 5 Phosphorylation in Immune Cell Subsets In vitro and following Interleukin-2 Immunotherapy. <i>Clinical Cancer Research</i> , 2006, 12, 5850-5858.	7.0	31
99	A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN- $\gamma$ -2b in patients with CEA-expressing carcinomas. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1353-1364.	4.2	31
100	Increased breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature. <i>Hereditary Cancer in Clinical Practice</i> , 2019, 17, 12.	1.5	31
101	Fc $\gamma$ 3R-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways. <i>Blood</i> , 2006, 108, 718-725.	1.4	30
102	Gene Expression Profiling Reveals Similarities between the <i>In vitro</i> and <i>In vivo</i> Responses of Immune Effector Cells to IFN- $\gamma$ . <i>Clinical Cancer Research</i> , 2008, 14, 5900-5906.	7.0	30
103	A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 4955-4965.	7.0	30
104	Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 815-825.	4.2	29
105	Fluorescent nanodiamonds engage innate immune effector cells: A potential vehicle for targeted anti-tumor immunotherapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 909-920.	3.3	29
106	Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON. <i>Cancer Immunology Research</i> , 2018, 6, 671-684.	3.4	29
107	VEGF Secretion is Inhibited by Interferon-Alpha in Several Melanoma Cell Lines. <i>Journal of Interferon and Cytokine Research</i> , 2008, 28, 553-562.	1.2	28
108	Monoclonal Antibody Therapy of Pancreatic Cancer With Cetuximab. <i>Journal of Immunotherapy</i> , 2012, 35, 367-373.	2.4	28

#	ARTICLE	IF	CITATIONS
109	Biphasic anaphylactic reaction to blue dye during sentinel lymph node biopsy. <i>World Journal of Surgical Oncology</i> , 2008, 6, 79.	1.9	27
110	Beta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients. <i>Psycho-Oncology</i> , 2013, 22, 1889-1894.	2.3	27
111	NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 4179-4184.	7.1	27
112	Novel rodent model of breast cancer survival with persistent anxiety-like behavior and inflammation. <i>Behavioural Brain Research</i> , 2017, 330, 108-117.	2.2	27
113	Phase I Study of the Sequential Combination of Interleukin-12 and Interferon Alfa-2b in Advanced Cancer: Evidence for Modulation of Interferon Signaling Pathways by Interleukin-12. <i>Journal of Clinical Oncology</i> , 2005, 23, 8835-8844.	1.6	26
114	A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma. <i>Journal of Immunology</i> , 2016, 197, 1489-1497.	0.8	26
115	Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. <i>Journal of Surgical Oncology</i> , 2018, 118, 501-509.	1.7	26
116	An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1379-1389.	4.2	26
117	Targeting tissue factor as a novel therapeutic oncotarget for eradication of cancer stem cells isolated from tumor cell lines, tumor xenografts and patients of breast, lung and ovarian cancer. <i>Oncotarget</i> , 2017, 8, 1481-1494.	1.8	26
118	Phase 2 Study of the g209-2M Melanoma Peptide Vaccine and Low-Dose Interleukin-2 in Advanced Melanoma. <i>Journal of Immunotherapy</i> , 2006, 29, 95-101.	2.4	25
119	Metastatic Melanoma: Lactate Dehydrogenase Levels and CT Imaging Findings of Tumor Devascularization Allow Accurate Prediction of Survival in Patients Treated with Bevacizumab. <i>Radiology</i> , 2014, 270, 425-434.	7.3	25
120	The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells. <i>Journal of Immunology</i> , 2015, 195, 1995-2005.	0.8	25
121	Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator. <i>Oncimmunology</i> , 2016, 5, e1214787.	4.6	25
122	A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2244-2250.	4.1	25
123	Plasma MicroRNA Levels Following Resection of Metastatic Melanoma. <i>Bioinformatics and Biology Insights</i> , 2017, 11, 117793221769483.	2.0	25
124	NK cell-based immunotherapy for treating cancer: will it be promising?. <i>The Korean Journal of Hematology</i> , 2011, 46, 3.	0.7	23
125	NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1337-1346.	4.9	23
126	Src Homology 2-Containing Inositol 5-Phosphatase 1 Negatively Regulates IFN- $\gamma$ Production by Natural Killer Cells Stimulated with Antibody-Coated Tumor Cells and Interleukin-12. <i>Cancer Research</i> , 2005, 65, 9099-9107.	0.9	21



#	ARTICLE	IF	CITATIONS
127	Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4+ and CD8+ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1281-1288.	4.2	21
128	Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer. <i>Oncolmmunology</i> , 2012, 1, 1004-1016.	4.6	21
129	Impact of breast cancer recurrence and cancer-specific stress on spouse health and immune function. <i>Brain, Behavior, and Immunity</i> , 2012, 26, 228-233.	4.1	21
130	Relationship satisfaction predicts lower stress and inflammation in breast cancer survivors: A longitudinal study of within-person and between-person effects. <i>Psychoneuroendocrinology</i> , 2020, 118, 104708.	2.7	21
131	Cytokine signaling-1 suppressor is inducible by IL-1beta and inhibits the catabolic effects of IL-1beta in chondrocytes: its implication in the paradoxical joint-protective role of IL-1beta. <i>Arthritis Research and Therapy</i> , 2013, 15, R191.	3.5	20
132	Re-emphasizing the concept of adequacy of intraoperative assessment of the axillary sentinel lymph nodes for identifying nodal positivity during breast cancer surgery. <i>World Journal of Surgical Oncology</i> , 2007, 5, 18.	1.9	19
133	A Pilot Study of Bevacizumab and Interferon-Î±2b in Ocular Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 87-91.	1.3	19
134	Brutonâ€™s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2439-2451.	4.2	19
135	Intronic miR-3151 Within BAALC Drives Leukemogenesis by Dereulating the TP53 Pathway. <i>Science Signaling</i> , 2014, 7, ra36.	3.6	18
136	Global microRNA profiling for diagnostic appraisal of melanocytic Spitz tumors. <i>Journal of Surgical Research</i> , 2016, 205, 350-358.	1.6	18
137	Antibody Conjugation of Fluorescent Nanodiamonds for Targeted Innate Immune Cell Activation. <i>ACS Applied Nano Materials</i> , 2021, 4, 3122-3139.	5.0	18
138	Folate-Immunoglobulin G as an Anticancer Therapeutic Antibody. <i>Bioconjugate Chemistry</i> , 2010, 21, 961-968.	3.6	17
139	Use of a nanoporous biodegradable miniature device to regulate cytokine release for cancer treatment. <i>Journal of Controlled Release</i> , 2011, 151, 239-245.	9.9	17
140	MicroRNA-3151 inactivates TP53 in BRAF -mutated human malignancies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E6744-51.	7.1	17
141	Interferon-Î³ Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells. <i>Journal of Biological Chemistry</i> , 2016, 291, 25656-25666.	3.4	17
142	A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma. <i>Journal of Immunotherapy</i> , 2014, 37, 180-186.	2.4	16
143	Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 9629-9634.	7.1	16
144	Interleukin 15: A Potential Player during the Innate Immune Response to Infection. <i>Experimental Parasitology</i> , 1996, 84, 291-294.	1.2	15

#	ARTICLE	IF	CITATIONS
145	IFN- $\gamma$ -2 $\beta$ “Induced Signal Transduction and Gene Regulation in Patient Peripheral Blood Mononuclear Cells Is Not Enhanced by a Dose Increase from 5 to 10 Megaunits/m <sup>2</sup> . <i>Clinical Cancer Research</i> , 2008, 14, 1438-1445.	7.0	15
146	Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleukin-12. <i>BMC Medical Genomics</i> , 2015, 8, 66.	1.5	15
147	Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 740890.	4.8	15
148	Heparin-binding EGF-like growth factor (HB-EGF) protects the intestines from radiation therapy-induced intestinal injury. <i>Journal of Pediatric Surgery</i> , 2013, 48, 1316-1322.	1.6	14
149	A nanoporous cell-therapy device with controllable biodegradation for long-term drug release. <i>Journal of Controlled Release</i> , 2013, 165, 226-233.	9.9	14
150	A Phase I Trial of Bortezomib and Interferon- $\alpha$ -2b in Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2014, 37, 55-62.	2.4	14
151	Evidence for interaction of the NLRP3 inflammasome and Bruton’s tyrosine kinase in tumor-associated macrophages: implications for myeloid cell production of interleukin-1 $\beta$ . <i>Oncolmmunology</i> , 2019, 8, 1659704.	4.6	13
152	Breast cancer survivors' satisfying marriages predict better psychological and physical health: A longitudinal comparison of satisfied, dissatisfied, and unmarried women. <i>Psycho-Oncology</i> , 2021, 30, 699-707.	2.3	13
153	Generation of stimulated, lymphokine activated T killer (T-LAK) cells from the peripheral blood of normal donors and adult patients with recurrent glioblastoma. <i>Journal of Immunological Methods</i> , 1991, 137, 225-235.	1.4	12
154	MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions. <i>Cancer Immunology Research</i> , 2017, 5, 778-789.	3.4	12
155	Classification of Indeterminate Melanocytic Lesions by MicroRNA Profiling. <i>Annals of Surgical Oncology</i> , 2017, 24, 347-354.	1.5	12
156	Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1137-1149.	4.2	11
157	Immune Modulation with Interleukin-21. <i>Annals of the New York Academy of Sciences</i> , 2009, 1182, 39-46.	3.8	11
158	Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions. <i>Melanoma Research</i> , 2016, 26, 329-337.	1.2	11
159	NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 120-131.	4.9	11
160	In Situ Deployment of Engineered Extracellular Vesicles into the Tumor Niche via Myeloid-Derived Suppressor Cells. <i>Advanced Healthcare Materials</i> , 2022, 11, e2101619.	7.6	11
161	Association of Allostatic Load With Overall Mortality Among Patients With Metastatic Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2022, 5, e2221626.	5.9	11
162	Interferon $\gamma$ and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects. <i>Surgery</i> , 2006, 140, 297-306.	1.9	10

#	ARTICLE	IF	CITATIONS
163	A Comprehensive Program for the Enhancement of Accrual to Clinical Trials. <i>Annals of Surgical Oncology</i> , 2016, 23, 2146-2152.	1.5	10
164	Within-person changes in cancer-related distress predict breast cancer survivors' inflammation across treatment. <i>Psychoneuroendocrinology</i> , 2020, 121, 104866.	2.7	10
165	Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-Negative Melanoma: Long-term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival. <i>Cancer Immunology Research</i> , 2014, 2, 981-987.	3.4	9
166	The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma. <i>Oncotarget</i> , 2016, 7, 81172-81186.	1.8	9
167	Rat Mitogen-Stimulated Lymphokine-Activated T Killer Cells. <i>Journal of Immunotherapy</i> , 1991, 10, 131-140.	2.4	8
168	Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 2031-2037.	4.2	7
169	A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 619-629.	4.2	7
170	Guided migration analyses at the single-clone level uncover cellular targets of interest in tumor-associated myeloid-derived suppressor cell populations. <i>Scientific Reports</i> , 2020, 10, 1189.	3.3	7
171	CD200 Blockade Modulates Tumor Immune Microenvironment but Fails to Show Efficacy in Inhibiting Tumor Growth in a Murine Model of Melanoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 739816.	3.7	7
172	Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma. <i>Melanoma Research</i> , 2018, 28, 390-397.	1.2	6
173	Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy. <i>Melanoma Research</i> , 2019, 29, 491-500.	1.2	6
174	Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells. <i>Clinical Lung Cancer</i> , 2021, 22, e487-e497.	2.6	6
175	Reciprocal Signaling between Myeloid Derived Suppressor and Tumor Cells Enhances Cellular Motility and is Mediated by Structural Cues in the Microenvironment. <i>Advanced Biology</i> , 2020, 4, 2000049.	3.0	6
176	Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer. <i>Journal of Hematology and Oncology</i> , 2021, 14, 15.	17.0	6
177	Getting Melanoma Cells to Stimulate With Frequency. <i>Journal of Clinical Oncology</i> , 2005, 23, 8929-8931.	1.6	5
178	Current Immunotherapeutic Strategies in Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2007, 16, 841-860.	1.5	5
179	Structural characterization of NRAS isoform 5. <i>Protein Science</i> , 2016, 25, 1069-1074.	7.6	5
180	NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines. <i>Cancer Immunology Research</i> , 2016, 4, 323-336.	3.4	5

#	ARTICLE	IF	CITATIONS
181	Soy-tomato enriched diet reduces inflammation and disease severity in a pre-clinical model of chronic pancreatitis. <i>Scientific Reports</i> , 2020, 10, 21824.	3.3	5
182	Analysis of potential biomarkers of response to IL-12 therapy. <i>Journal of Leukocyte Biology</i> , 2022, 112, 557-567.	3.3	5
183	Surgical management of ovarian carcinoma metastatic to the breast and axilla: A role for metastasectomy?. <i>Journal of Surgical Oncology</i> , 2015, 112, 581-584.	1.7	4
184	ASCO 2015 update on melanoma. <i>Surgical Oncology</i> , 2015, 24, 363-365.	1.6	4
185	MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5931-5941.	2.0	4
186	Tissue microRNA expression profiling in hepatic and pulmonary metastatic melanoma. <i>Melanoma Research</i> , 2020, 30, 455-464.	1.2	4
187	The gut connection: Intestinal permeability as a pathway from breast cancer survivors' relationship satisfaction to inflammation across treatment. <i>Brain, Behavior, and Immunity</i> , 2022, 100, 145-154.	4.1	4
188	Tumor Infiltrating Lymphocytes – The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast Cancer. <i>Journal of Carcinogenesis &amp; Mutagenesis</i> , 2014, 05, .	0.3	3
189	Fluorescent nanodiamonds and their use in biomedical research. , 2016, , .		3
190	Activation of the Fcγ3R on human natural killer cells leads to increased expression of functional interleukin-21 receptor. <i>Oncolmmunology</i> , 2017, 6, e1312045.	4.6	3
191	Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. , 2001, 31, 3016.		3
192	Unusual recurrence of breast cancer in a BRCA1 variant patient after fat grafting. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 2457-2462.	0.5	2
193	Neoadjuvant chemotherapy in bladder cancer: Clinical benefit observed in prospective trials computed with restricted mean survival times. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 435.e17-435.e22.	1.6	2
194	Loss of miR-1469 expression mediates melanoma cell migration and invasion. <i>PLoS ONE</i> , 2021, 16, e0256629.	2.5	2
195	Braking Bad: Blockade of Inhibitory Pathways Improves Interleukin-15 Therapy. <i>Clinical Cancer Research</i> , 2010, 16, 5917-5919.	7.0	1
196	Immunotherapy comes of age: overview of the 21st Annual Meeting and associated programs of the International Society for Biological Therapy of Cancer. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 419-422.	3.1	0
197	Concurrent phyllodes tumor, eccrine carcinoma, and multinodular goiter 20 years after radiotherapy for Hodgkin lymphoma. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 2498-2503.	0.5	0
198	Characterization of inflammatory changes in the breast cancer associated adipose tissue and comparison to the unaffected contralateral breast. <i>Surgical Oncology</i> , 2021, 39, 101659.	1.6	0